Publications
bioRxiv : the preprint server for biologyApr 2024 DOI:
10.1101/2024.04.03.588009

Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers

Boruah, Nabamita; Hoyos, David; Moses, Renyta; Hausler, Ryan; Desai, Heena; Le, Anh N; Good, Madeline; Kelly, Gregory; Raghavakaimal, Ashvathi; Tayeb, Maliha; Narasimhamurthy, Mohana; Doucette, Abigail; Gabriel, Peter; Feldman, Michael J; Park, Jinae; de Rodas, Miguel Lopez; Schalper, Kurt A; Goldfarb, Shari B; Nayak, Anupma; Levine, Arnold J; Greenbaum, Benjamin D; Maxwell, Kara N
Product Used
Variant Libraries
Abstract
Pathogenic germline TP53 alterations cause Li-Fraumeni Syndrome (LFS), and breast cancer is the most common cancer in LFS females. We performed first of its kind multimodal analysis of LFS breast cancer (LFS-BC) compared to sporadic premenopausal BC. Nearly all LFS-BC underwent biallelic loss of TP53 with no recurrent oncogenic variants except ERBB2 (HER2) amplification. Compared to sporadic BC, in situ and invasive LFS-BC exhibited a high burden of short amplified aneuploid segments (SAAS). Pro-apoptotic p53 target genes BAX and TP53I3 failed to be up-regulated in LFS-BC as was seen in sporadic BC compared to normal breast tissue. LFS-BC had lower CD8+ T-cell infiltration compared to sporadic BC yet higher levels of proliferating cytotoxic T-cells. Within LFS-BC, progression from in situ to invasive BC was marked by an increase in chromosomal instability with a decrease in proliferating cytotoxic T-cells. Our study uncovers critical events in mutant p53-driven tumorigenesis in breast tissue.
Product Used
Variant Libraries

Related Publications